Stable cell lines, especially those for protein and antibody production.
C014: GONAL-F Biosimilar Stable Cell Line (CHO)
The yield of GONAL-F biosimilar from the CHO stable cell line was above 100 mg/L.
C002: Erbitux Biosimilar Stable Cell Line (CHO)
The yield of Erbitux biosimilar from the CHO stable cell line was above 1.7 g/L in a 750 liter manufacturing.
C009: Herceptin Biosimilar Stable Cell Line (CHO)
The yield of Herceptin biosimilar from the CHO stable cell line was above 2.0 g/L in a 3 liter manufacturing.
C003: Humira Biosimilar Stable Cell Line (CHO)
The yield of Humira biosimilar from the CHO stable cell line was above 2.0 g/L in a 50 liter manufacturing.
C005: Lucentis Biosimilar Cell Line (E. coli)
The yield of Lucentis biosimilar from E.coli was above 36 mg/L in a 7.5 liter manufacturing.
C022: Eculizumab Biosimilar Stable Cell Line (CHO)
The Eculizumab biosimilar stable cell line alone can be transferred alone or together with the technology of process development and/or antibody purification.
C001: Avastin Biosimilar Stable Cell Line (CHO)
The yield of Avastin biosimilar from the CHO stable cell line was above 1.7 g/L in a 750 liter manufacturing.
C010: Rituxan Biosimilar Stable Cell Line (CHO)
The yield of Rituxan biosimilar from the CHO stable cell line was above 1.8 g/L in a 3 liter manufacturing.
C021: Synagis Biosimilar Stable Cell Line (CHO)
The Synagis biosimilar stable cell line alone can be transferred alone or together with the technology of process development and/or antibody purification.
C011: Remicade Biosimilar Stable Cell Line (CHO)
The yield of Remicade biosimilar from the CHO stable cell line was above 1.5 g/L in flask.